VistaJet records 137% increase in U.S. flights in 2016
25.1.2017 18:05 | NASDAQ OMX
MALTA, 2017-01-25 18:05 CET (GLOBE NEWSWIRE) --
Global aviation service VistaJet reports 2016 as its best year ever in North America. The company, which positions itself as an alternative to full or fractional aircraft ownership, now reports the U.S. as its number one growth market, citing a preference for a global flying solution with no asset exposure as the reason customers choose to switch.
Photos accompanying this announcement are available at
In 2016, the number of flight bookings grew by 137% YoY across the VistaJet owned fleet1, connecting customers to 187 countries in the world. Over 65% of VistaJet US Inc’s2 new customers came from corporations and Fortune 500 companies favoring its signature business model to help them connect and do business worldwide.
International and American passengers arriving and departing from the U.S. grew 122% vs 2015, making it the number one country for take-offs and landings. VistaJet’s 71-strong fleet of Bombardier Challenger and Global aircraft1 are positioned all over the world to take customers anywhere with minimal notice. From popular cities such as New York or London, corporations and ultra high net worth individuals were able to arrange their flight with full catering in as little as 90 minutes from booking.
VistaJet promises the highest standards of safety and service. On board its silver and red-striped aircraft1, the company encourages customers to order catering from a restaurant of their choice; and has arranged for dishes from renowned Japanese restaurant Nobu to exclusive kosher restaurant and bakery My Most Favorite Food.
Rather than fractional or full aircraft ownership, VistaJet pioneered the asset-free hourly subscription model to arrange for flight services worldwide. Continued global growth and an ongoing partnership with U.S. operator and General Dynamics-owned subsidiary Jet Aviation further positions VistaJet as a favorite alternative for American customers.
Chairman and Founder Thomas Flohr said: “I want to say thank you to our U.S. customers and partners for welcoming the VistaJet business model with open arms. North America has the most mature business aviation market in the world, so for us to experience such advanced growth in a short time frame is a true indication that this market is ready for change.
We’re excited to give customers a new option, arranging for flights to more cities in the U.S. and around the globe, in collaboration with our partner, Jet Aviation.”
1 VistaJet owned and U.S. registered aircraft are operated by duly licensed U.S. air carriers. VistaJet and its U.S. subsidiary, VistaJet US, Inc., are not U.S. direct or indirect air carriers. Any reference to ‘the fleet’ or ‘aircraft’ include own-operated or partner operated aircraft.
2 VistaJet US Inc. acts as agent of the client or as sourcing agent for duly licensed U.S. air carriers depending on the selected services.
Founded in 2004 by Thomas Flohr, VistaJet is now the first and only truly global aviation company. On its fleet of specially designed business jets1, VistaJet arranges flights for corporations, governments and private clients to 187 countries worldwide. The Company pioneered the ‘pay the hours you fly’ business model, providing all the benefits of owning a personal jet without the responsibilities or asset risk of aircraft ownership. VistaJet’s signature Program service offers a bespoke subscription of flight hours on its global fleet1, with the guarantee to fly anywhere, at any time. News and information are available at www.vistajet.com, or for the U.S., use www.vistajet.com/us
T: +44 203 617 3077
T: +1 917 225 0370
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Hminers Disrupts the Cryptocurrency Market with Powerful, Multi-Algorithm Mining Rigs18.8.2017 11:00 | Pressemelding
Hminers continues to hit the headlines in the rapidly expanding global market for cryptocurrency. The Miami-based company has recently introduced three extremely powerful, multi-algorithm mining rigs that have been designed to provide maximum hash rate with minimum power consumption. MIAMI, Aug. 18, 2017 (GLOBE NEWSWIRE) -- In their relentless efforts to deliver state-of-the-art products related to cryptocurrency, Hminers has recently launched three brilliantly designed bitcoin mining rigs. The unique features and capabilities of the company's new H2U Miner, H4U Miner, and Rack Equipped with 5 x H4U have already grabbed the attention of the cryptocurrency enthusiasts and experts around the world. An organization with a rich tradition, Hminers (www.hminers.com) is recognized in the industry as the creator of the first ever 10 nm ASIC Chip in the world. Cryptocurrency mining is the process of generating new cryptocurrency that requires a pot
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50 | Pressemelding
NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market. I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30 | Pressemelding
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00 | Pressemelding
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S. RedHill's GI-focused sales force currently promotes two GI s
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40 | Pressemelding
Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38 | Pressemelding
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom